Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

ABZYME THERAPEUTICS LLC

UEI: H2MLEFWV36N6CAGE: 62ES6

ABZYME THERAPEUTICS LLC is a federal contractor, registered under UEI H2MLEFWV36N6 and CAGE code 62ES6. It has been awarded $9,008,277 across 23 federal contracts. Primary work spans Unknown NAICS, Research and Development in Biotechnology (except Nanobiotechnology), and Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Top awarding agencies include Department Of Health And Human Services, Department Of Defense, and Department Of Agriculture.

Contact Information

Registration and classification details

Registration

UEI Code

H2MLEFWV36N6

CAGE Code

62ES6

Entity Structure

Partnership or Limited Liability Partnership

Established

N/A

Business Classifications

232XFRLJ

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ABZYME THERAPEUTICS LLC operates in the scientific research and development sector, with a primary focus on advanced therapeutic discovery and preclinical development. Based on its NAICS code 541714, the company specializes in biotechnological research, including molecular biology, protein engineeri...

ABZYME THERAPEUTICS LLC operates in the scientific research and development sector, with a primary focus on advanced therapeutic discovery and preclinical development. Based on its NAICS code 541714, the company specializes in biotechnological research, including molecular biology, protein engineering, and targeted drug delivery systems. Their technical expertise likely encompasses assay development, high-throughput screening, pharmacokinetic and pharmacodynamic modeling, and translational research bridging laboratory findings to clinical applications. As a small business entity structured as a 2K (small business concern), ABZYME THERAPEUTICS LLC positions itself as a nimble innovator in early-stage biopharmaceutical R&D, emphasizing precision medicine and novel therapeutic modalities. No award history is available to confirm specific agency engagements, so no definitive patterns of government client relationships can be inferred. Similarly, without contract data, it is not possible to identify primary federal customers or the nature of any prior government-funded projects. The company’s industry focus is aligned with scientific R&D in life sciences, particularly in therapeutic development for unmet medical needs. This includes work in biologics, small-molecule drug candidates, and potentially gene or cell-based therapies, though specific verticals cannot be confirmed from available data. ABZYME THERAPEUTICS LLC is a small business headquartered in Pottstown, Pennsylvania, with no publicly disclosed government certifications such as 8(a), HUBZone, or WOSB. Its geographic presence is localized, and its government market positioning appears to be that of a specialized R&D provider seeking opportunities in federal biomedical research programs, though no past performance or client relationships are documented in the available records.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$7.6M83.9%
Department Of Defense$1.2M13.9%
Department Of Agriculture$199.9K2.2%
Awards by NAICS
- Unknown NAICS$7.2M79.5%
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$1.3M14.4%
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)$299.8K3.3%
541711 - Research and Development in Biotechnology$149.7K1.7%
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)$100.0K1.1%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in ABZYME THERAPEUTICS LLC's top NAICS codes and agencies

New
Federal
PEO-FW Group 2 Air-Launched Effects (A2E) Assessment Event (AE)
Solicitation # PEO_FW_Group_2_Air_Launched_Effects_A2E_Assessment_Event_AE
SOFWERX and the USSOCOM Program Executive Office Fixed Wing are hosting an Assessment Event to identify vendors capable of integrating existing compatible small, unmanned air system platforms into a Karman Systima Common Launch Tube. This initiative supports the Adaptive Airborne Enterprise program, which aims to enhance ISR capabilities through autonomous platforms and resilient data paths. The government is specifically seeking TRL 5+ airframes that can be rapidly integrated to support Find, Fix, Track, Target, and Electronic Warfare missions under the Air Force Special Operations Command. Participation is limited to U.S. citizens, and the event is open to industry, academia, and national laboratories. The engagement follows a multi-phase timeline beginning with a submission period that closes on 11 September 2026. Following a downselect process in late September, selected participants will attend a virtual Assessment Event on 07 October 2026 to pitch and demonstrate their solutions to a USSOCOM evaluation panel. Successful evaluations may lead to various agreement types, including research and development agreements, Other Transaction Authorities for prototypes, or FAR-based procurement contracts. Potential awardees may also be required to maintain compliance with NIST SP 800-171 standards for protecting controlled unclassified information.
Department Of Defense

POSTED

about 6 hours ago

DEADLINE

in 18 days
View Details
NAICS: 212323
New
Federal
Request for Information Commercial Clay Source for New Orleans to Venice (NOV), Louisiana (LA) Projects Hurricane and Storm Damage Risk Reduction System
Solicitation # W912EQ26N3401
The U.S. Army Corps of Engineers is conducting market research through a Request for Information (RFI) to identify commercially available clay material sources to support the New Orleans to Venice (NOV), Louisiana Hurricane and Storm Damage Risk Reduction System (HSDRRS). The project requires approximately 5,000,000 cubic yards of clay, with construction contracts anticipated to be awarded between the fourth quarter of Fiscal Year 2027 and the fourth quarter of Fiscal Year 2030. The overall project is scheduled for completion by the end of 2035. This RFI is for information and planning purposes only and does not constitute a formal solicitation or a guarantee of contract award. Interested firms must submit a comprehensive package that includes their business size, socioeconomic status, and a Statement of Capability. Submissions must strictly adhere to the 14 mandatory requirements outlined in Appendix A, which cover regulatory, environmental, and technical specifications. Key requirements include providing a signed Right of Entry, topographic and site layout maps, wetland determinations, coastal zone management permits, and cultural resource reports. Additionally, potential sources must provide geotechnical reports stamped by a licensed professional engineer, confirming that the clay meets specific soil classification standards (CL or CH) and adheres to strict limits regarding organic content, sand content, and salinity. All technical documentation and environmental assessments must be current, typically updated within the last 6 to 12 months. Responses must be submitted via the DoD SAFE portal to the designated point of contact no later than 11:00 A.M. on August 31, 2026.
Department Of Defense

POSTED

about 6 hours ago

DEADLINE

in 7 days
View Details